Proactive Investors - Run By Investors For Investors

Hemogenyx reports encouraging data for bone marrow transplant therapy

"This new data demonstrates our continuing progress in developing potential uses for our CDX antibody.”
CDX antibody helps the body target cancerous cells

HemoGenyx Pharmaceuticals PLC (LON:HEMO) found good gains on Wednesday after it said pre-clinical trials in animals indicate its CDX antibody is effective as a conditioning therapy in bone marrow transplants.

Conditioning is a pre-requisite for a transplant but it is extremely toxic and has severe side effects, which reduces the number of people eligible.

READ: Hemogenyx soars as CDX antibody demonstrates effectiveness against acute myeloid leukemia

In vivo data showed CDX helps the human body’s own defences (T-cells) to target the cancerous cells.

Vladislav Sandler, Hemogenyx’s chief executive, said he was ‘much encouraged by this new data’.

"This new data demonstrates our continuing progress in developing potential uses for our CDX antibody.”

Today’s results are the latest in a string of promising updates about CDX from Hemogenyx.

Over the past two weeks, lab test results showed the antibody was effective against two types of blood cancer: acute myeloid leukemia and acute lymphoblastic leukemia, where transplants are the standard treatment.

In afternoon trading, shares in Hemogenyx were 7.7% higher at 2.80p.

 -- Adds share price --

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Related Articles

January 28 2019
"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use